<- Go Home
ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Market Cap
N/A
Volume
105.5K
Cash and Equivalents
EUR 516.7M
EBITDA
-EUR 245.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 4.6M
Profit Margin
100.00%
52 Week High
EUR 132.00
52 Week Low
EUR 5.00
Dividend
N/A
Price / Book Value
16.49
Price / Earnings
N/A
Price / Tangible Book Value
17.45
Enterprise Value
EUR 7.1B
Enterprise Value / EBITDA
-29.07
Operating Income
-EUR 246.1M
Return on Equity
135.58%
Return on Assets
-38.95
Cash and Short Term Investments
EUR 530.4M
Debt
EUR 32.1M
Equity
EUR 455.2M
Revenue
EUR 4.6M
Unlevered FCF
-EUR 100.5M
Sector
Biotechnology
Category
N/A